Published in Drug Des Devel Ther on June 19, 2013
Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF) | NCT01170065
The treatment of idiopathic pulmonary fibrosis. F1000Prime Rep (2014) 0.86
Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis. Respir Res (2015) 0.81
Protective role of andrographolide in bleomycin-induced pulmonary fibrosis in mice. Int J Mol Sci (2013) 0.80
Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies. J Thorac Dis (2015) 0.80
Role of Receptor Tyrosine Kinase Signaling in Renal Fibrosis. Int J Mol Sci (2016) 0.79
Attenuating endogenous Fgfr2b ligands during bleomycin-induced lung fibrosis does not compromise murine lung repair. Am J Physiol Lung Cell Mol Physiol (2015) 0.78
VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol (2006) 12.09
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (2011) 5.94
Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2006) 5.86
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2005) 5.83
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med (2012) 5.33
Idiopathic pulmonary fibrosis. Lancet (2011) 5.25
Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J (2009) 4.63
Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov (2012) 4.30
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med (2011) 3.85
Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest (2001) 3.72
Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest (2004) 3.44
Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 3.37
Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev (2004) 3.14
TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell (1990) 2.82
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res (2008) 2.76
The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax (2011) 2.76
Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med (2009) 2.63
Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis. N Engl J Med (1987) 2.62
Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax (2006) 2.59
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 2.54
Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J (2007) 2.47
The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol (1997) 2.41
Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest (1990) 2.29
Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest (2007) 2.28
Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med (2005) 2.25
The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med (2009) 2.18
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol (2011) 2.06
A detailed evaluation of acute respiratory decline in patients with fibrotic lung disease: aetiology and outcomes. Respirology (2010) 1.80
Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J (2007) 1.78
Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax (2012) 1.65
Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. Am J Pathol (1999) 1.42
VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. J Clin Invest (2009) 1.41
Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit Care Med (2002) 1.37
Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res (2009) 1.32
Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med (2002) 1.27
Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J Immunol (2005) 1.27
Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. Am J Respir Crit Care Med (2012) 1.26
Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther (2011) 1.26
Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol (2011) 1.24
Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol (1999) 1.21
A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor beta 1, or platelet-derived growth factor B gene. Proc Natl Acad Sci U S A (1995) 1.21
Idiopathic pulmonary fibrosis and pirfenidone. Eur Respir J (2010) 1.18
A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol (2011) 1.15
TNF-alpha stimulation of fibroblast proliferation. Dependence on platelet-derived growth factor (PDGF) secretion and alteration of PDGF receptor expression. J Immunol (1995) 1.08
Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res (2010) 1.06
Identification and partial characterization of angiogenesis bioactivity in the lower respiratory tract after acute lung injury. J Clin Invest (1991) 1.00
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem (2009) 0.99
Localization of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung. Am J Respir Crit Care Med (1995) 0.99
The increasing secondary care burden of idiopathic pulmonary fibrosis: hospital admission trends in England from 1998 to 2010. Chest (2013) 0.94
Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther (2010) 0.91
Pirfenidone in idiopathic pulmonary fibrosis. Drugs Today (Barc) (2010) 0.88
A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. Ann Oncol (2009) 0.88
Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer. Anticancer Res (2011) 0.85
Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica (2011) 0.84
Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor. Invest New Drugs (2011) 0.81
An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma. Anticancer Res (2009) 0.81
Mutant soluble ectodomain of fibroblast growth factor receptor-2 IIIc attenuates bleomycin-induced pulmonary fibrosis in mice. Biol Pharm Bull (2012) 0.80
Reduction of cell proliferation induced by PD166866: an inhibitor of the basic fibroblast growth factor. J Exp Clin Cancer Res (2007) 0.80
Selection of peptide ligands binding to fibroblast growth factor receptor 1. IUBMB Life (2002) 0.77
New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond. Ther Clin Risk Manag (2011) 0.77
Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med (2008) 3.19
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet (2013) 3.17
Utility of endobronchial ultrasound-guided transbronchial needle aspiration in patients with tuberculous intrathoracic lymphadenopathy: a multicentre study. Thorax (2011) 2.60
A comparison between two strategies for monitoring hepatic function during antituberculous therapy. Am J Respir Crit Care Med (2011) 2.22
Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax (2013) 2.17
The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2014) 2.17
Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest (2009) 1.96
Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2014) 1.73
Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes. Eur Respir J (2012) 1.67
Obliterative bronchiolitis in fibreglass workers: a new occupational disease? Occup Environ Med (2013) 1.54
Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). Am J Pathol (2009) 1.50
Incidence of the pneumoconioses in the United Kingdom general population between 1997 and 2008. Respiration (2012) 1.41
The role of infection in the pathogenesis of idiopathic pulmonary fibrosis. Eur Respir Rev (2013) 1.04
Rituximab in severe, treatment-refractory interstitial lung disease. Respirology (2013) 1.03
Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J (2012) 1.02
Lung microbiology and exacerbations in COPD. Int J Chron Obstruct Pulmon Dis (2012) 1.01
Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol (2013) 0.99
The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax (2012) 0.98
Increased survivin expression contributes to apoptosis-resistance in IPF fibroblasts. Adv Biosci Biotechnol (2012) 0.98
Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther (2014) 0.94
18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials. Eur J Nucl Med Mol Imaging (2011) 0.94
Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug Des Devel Ther (2012) 0.93
Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients. Eur J Nucl Med Mol Imaging (2013) 0.92
Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease. Respir Res (2013) 0.91
Primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis: one step at a time. Am J Respir Crit Care Med (2013) 0.86
Vibration response imaging technology in healthy subjects. AJR Am J Roentgenol (2008) 0.86
Novel use of rituximab in hypersensitivity pneumonitis refractory to conventional treatment. Thorax (2013) 0.86
Pulmonary function vascular index predicts prognosis in idiopathic interstitial pneumonia. Respirology (2012) 0.85
Performance of Xpert MTB/RIF in the diagnosis of tuberculous mediastinal lymphadenopathy by endobronchial ultrasound. Ann Am Thorac Soc (2014) 0.85
Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis. Eur Respir J (2013) 0.83
Evidence for a functional thymic stromal lymphopoietin signaling axis in fibrotic lung disease. J Immunol (2013) 0.83
Personalized medicine in idiopathic pulmonary fibrosis: facts and promises. Curr Opin Pulm Med (2015) 0.83
Improved correction for the tissue fraction effect in lung PET/CT imaging. Phys Med Biol (2015) 0.82
Drug-/radiation-induced interstitial lung disease in the United Kingdom general population: incidence, all-cause mortality and characteristics at diagnosis. Respirology (2012) 0.80
Diffuse cystic lung disease of unexplained cause with coexistent small airway disease: a possible causal relationship? Am J Surg Pathol (2012) 0.80
In search of the fibrotic epithelial cell: opportunities for a collaborative network. Thorax (2011) 0.80
Exercise-induced haemoptysis: a thoroughbred cause? Thorax (2013) 0.80
The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease. Respir Med (2013) 0.78
Year in review 2013: Acute lung injury, interstitial lung diseases, sleep and physiology. Respirology (2014) 0.77
Lost in translation; from animal models of pulmonary fibrosis to human disease. Respirology (2009) 0.77
Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies. Sarcoidosis Vasc Diffuse Lung Dis (2014) 0.76
Sildenafil in idiopathic pulmonary fibrosis. N Engl J Med (2010) 0.75
Year in review 2012: acute lung injury, interstitial lung diseases, sleep and physiology. Respirology (2013) 0.75
Understanding nonspecific interstitial pneumonia: the need for a diagnostic gold standard. Am J Respir Crit Care Med (2009) 0.75
Detecting anxiety and depression in patients diagnosed with an interstitial lung disease. Can we do better? Respirology (2014) 0.75
Idiopathic pulmonary fibrosis-related pulmonary hypertension; an exercising diagnosis? Respirology (2011) 0.75
Pulmonary fibrosis associated with psychotropic drug therapy: a case report. J Med Case Rep (2009) 0.75
Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis. Thorax (2013) 0.75
If it was good enough for Aristotle...... Thorax (2011) 0.75
Successful treatment of progressive diffuse PEComatosis. Eur Respir J (2012) 0.75
Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone. Respiration (2017) 0.75
Challenges in the classification of fibrotic ILD. Sarcoidosis Vasc Diffuse Lung Dis (2015) 0.75
Microbiome in interstitial lung disease: from pathogenesis to treatment target. Curr Opin Pulm Med (2017) 0.75
Pleuroparenchymal Fibroelastosis: A Review of Histopathologic Features and the Relationship Between Histologic Parameters and Survival. Am J Surg Pathol (2017) 0.75
Year in review 2010: interstitial lung diseases, acute lung injury, sleep, physiology, imaging, bronchoscopic intervention and lung cancer. Respirology (2011) 0.75
Year in review 2009: Interstitial lung diseases, acute injury, sleep, physiology, imaging and bronchoscopic intervention. Respirology (2010) 0.75
Year in review 2011: acute lung injury, interstitial lung diseases, physiology, sleep and lung cancer. Respirology (2012) 0.75
The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status. Thorax (2012) 0.75